Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention
Journal of the Foundations of Ophthalmology · 21.04.2026
DOI: 10.48089/jfo7689135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Foundations of Ophthalmology, online erschienen am 21.04.2026. Verfasst von Arslan Raja.
Abstract (Originalsprache)
Hydroxychloroquine (HCQ) is widely prescribed in the United Kingdom for autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. Although generally safe, long-term use is associated with a risk of retinal toxicity, which may result in irreversible visual impairment. Hydroxychloroquine retinopathy (HCR) is often asymptomatic in its early stages, making structured screening programmes essential. In response to emerging evidence of higher-than-previously recognised prevalence, the Royal College of Ophthalmologists has developed national guidelines for monitoring. This article reviews the pathophysiology, risk factors, clinical features, UK-based screening recommendations, and management strategies for HCR, with emphasis on prevention and early detection.
Zitieren
APA
Raja, A. (2026). Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention. Journal of the Foundations of Ophthalmology. https://doi.org/10.48089/jfo7689135
Vancouver
Raja A. Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention. Journal of the Foundations of Ophthalmology. 2026. doi:10.48089/jfo7689135
BibTeX
@article{Raja2026,
author = {Raja, Arslan},
title = {Hydroxychloroquine Retinopathy: Screening, Risk Stratification, and Prevention},
journal = {Journal of the Foundations of Ophthalmology},
year = {2026},
doi = {10.48089/jfo7689135}
}
EUVIMED